RVMD — Revolution Medicines Cashflow Statement
0.000.00%
Last trade - 00:00- $18.33bn
- $16.58bn
Annual cashflow statement for Revolution Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -187 | -249 | -436 | -600 | -1,131 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 27 | 32.8 | 42.9 | 34.6 | 138 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 8.72 | -13.1 | 40.7 | 1.17 | 86.8 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -147 | -224 | -351 | -557 | -898 |
| Capital Expenditures | -6.53 | -10.8 | -7.73 | -10.3 | -16 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -136 | -13.3 | -335 | -544 | 134 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -142 | -24.1 | -343 | -554 | 118 |
| Financing Cash Flow Items | -0.424 | 0.042 | 837 | 0.284 | 0.22 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 294 | 301 | 1,229 | 959 | 622 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 4.88 | 52.9 | 536 | -152 | -158 |